A previous study demonstrated that combining anti-CTLA-4 mAB and targeting mucin1 (MUC1), a tumor antigen, with cancer vaccines led to synergistic activation and cytotoxic T-cell expansion [56, 65, 71] (Fig. 2). This evidence concerns the gene CTLA4 and neoplasm.